Aduro Biotech Announces Management Changes
January 05 2018 - 8:00AM
Aduro Biotech, Inc. (NASDAQ:ADRO) a biopharmaceutical company with
three distinct immunotherapy technologies, today announced that
Jennifer Lew has been promoted to chief financial officer. Ms. Lew,
who previously served as the company’s senior vice president of
finance, will oversee the company’s global finance operations,
including accounting, planning, and investor relations functions.
Separately, Gregory W. Schafer will be stepping down from his
position as chief operating officer in early March and has agreed
to continue as a consultant to the company to facilitate a smooth
transition of responsibilities.
“I am very pleased to congratulate Jen, an important and valued
leader in the organization, on a well-deserved promotion,” said
Stephen T. Isaacs, chairman, president and chief executive officer
of Aduro. “Jen has played an integral role at Aduro, including
participating in the company’s 2015 initial public offering and in
maintaining the company’s strong cash position.”
Steve continued, “I want to thank Greg for his tremendous
contributions in the growth and development of Aduro these last
four years. His expertise and leadership were essential to securing
key partnerships and building the robust pipeline we have
today.”
Jennifer LewJennifer Lew joined Aduro in
October 2013 and has served as our Senior Vice President of Finance
since January 2015. Prior to joining Aduro, from 2004 to 2013, Ms.
Lew held various positions of increasing responsibility at Dynavax
Technologies, culminating as Vice President of Finance and
Principal Accounting Officer responsible for all accounting and
finance operations. Earlier in her career Ms. Lew served as
Assistant Controller and Director of Finance at QRS Corporation, a
publicly-held technology company, and was a member of the audit
practice at Ernst & Young. Ms. Lew earned a B.A. in
Economics/Accounting and Government from Claremont McKenna College
and is a Certified Public Accountant (inactive status).
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's STING Pathway
Activator platform is designed to activate the STING receptor in
immune cells, resulting in a potent tumor-specific immune response.
ADU-S100 is the first STING Pathway Activator compound to enter the
clinic and is currently being evaluated in both a Phase 1
monotherapy study as well as a Phase 1b combination study with an
anti-PD1 immune checkpoint inhibitor. Aduro’s B-select monoclonal
antibody platform is comprised of a number of immune modulating
assets in research and development, including BION-1301, an
anti-APRIL antibody. Aduro's pLADD program is based on proprietary
attenuated strains of Listeria that have been engineered to express
tumor neoantigens that are specific to an individual patient’s
tumor. Other Listeria strains for lung and prostate cancers are
being advanced by a partner. Aduro is collaborating with leading
global pharmaceutical companies to expand its products and
technology platforms. For more information, please visit
www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, the potential for our technology
platforms, plans, and the potential for eventual regulatory
approval of our product candidates. In some cases, you can identify
these statements by forward-looking words such as “may,” “will,”
“continue,” “plan,” “anticipate,” “intend,” “could,” “project,”
“seek,” “expect,” “position” or the negative or plural of these
words or similar expressions. Forward-looking statements are
not guarantees of future performance and are subject to risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated, including, but not limited to,
our history of net operating losses and uncertainty regarding our
ability to achieve profitability, our ability to develop and
commercialize our product candidates, our ability to use and expand
our technology platforms to build a pipeline of product candidates,
our ability to obtain and maintain regulatory approval of our
product candidates, our ability to operate in a competitive
industry and compete successfully against competitors that have
greater resources than we do, our reliance on third parties, and
our ability to obtain and adequately protect intellectual property
rights for our product candidates. We discuss many of these
risks in greater detail under the heading “Risk Factors” contained
in our quarterly report on Form 10-Q for the quarter ended
September 30, 2017, which is on file with the Securities and
Exchange Commission. Any forward-looking statements that we make in
this press release speak only as of the date of this press release.
We assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
Contact:
Alexandra Santos
Corporate Affairs & Investor
Relations
510 809 9231
Media Contact: Aljanae Reynolds 510 809 2452 press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Sep 2023 to Sep 2024